Quick Answer
Janux Therapeutics, Inc. reported Net Income of -$113.62 million for fiscal year 2025.
Janux Therapeutics, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Net Income | -$113.62M -64.7% |
-$68.99M -18.4% |
-$58.29M +7.6% |
-$63.06M -93.0% |
-$32.67M -381.6% |
-$6.78M |
| Diluted EPS | -$1.83 -43.0% |
-$1.28 +3.0% |
-$1.32 +13.2% |
-$1.52 -9.4% |
-$1.39 | — |
| Total Assets | $1.00B -5.6% |
$1.06B +179.0% |
$380.41M +4.5% |
$364.01M -4.2% |
$379.82M +2242.1% |
$16.22M |
| Cash and Equivalents | $52.33M -87.8% |
$430.61M +2142.2% |
$19.20M -62.7% |
$51.43M +44.5% |
$35.58M +355.4% |
$7.81M |
| Stockholders Equity | $956.82M -6.4% |
$1.02B +197.0% |
$344.35M +7.4% |
$320.74M -12.4% |
$366.33M +2602.6% |
-$14.64M -84.3% |
| R&D Expense | $125.90M +84.1% |
$68.39M +24.5% |
$54.92M +2.8% |
$53.44M +103.7% |
$26.24M +762.8% |
$3.04M |
| Operating Income | -$157.67M -59.5% |
-$98.85M -35.4% |
-$72.98M -8.8% |
-$67.09M -103.7% |
-$32.93M -579.9% |
-$4.84M |
| Shares Outstanding | 60.38M +2.2% |
59.06M +27.7% |
46.25M +11.1% |
41.62M +0.9% |
41.24M +3840.7% |
1.05M |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$24.31M | +13.4% | +28.2% |
| Diluted EPS | September 30, 2025 | -$0.39 | +23.5% | +29.1% |
| Total Assets | September 30, 2025 | $1.02B | +47.4% | -0.7% |
| Cash and Equivalents | September 30, 2025 | $48.39M | +80.9% | -7.7% |
| Stockholders Equity | September 30, 2025 | $976.55M | +48.8% | -1.4% |
| R&D Expense | September 30, 2025 | $34.63M | +86.0% | -0.1% |
| Operating Income | September 30, 2025 | -$35.25M | +1.6% | +21.9% |
| Shares Outstanding | September 30, 2025 | 60.12M | +14.9% | +1.4% |
- Janux Therapeutics, Inc. reported Net Income of -$113.62 million for fiscal year 2025.
- Janux Therapeutics, Inc. showed a decrease of -64.7% in Net Income compared to the prior fiscal year.
- Janux Therapeutics, Inc. reported Diluted EPS of $1.83 per share (loss) for fiscal year 2025.
- Janux Therapeutics, Inc. showed a decrease of -43.0% in Diluted EPS compared to the prior fiscal year.
- Janux Therapeutics, Inc. reported Total Assets of $1.00 billion for fiscal year 2025.
- Janux Therapeutics, Inc. showed a decrease of -5.6% in Total Assets compared to the prior fiscal year.
- Janux Therapeutics, Inc. reported Cash and Equivalents of $52.33 million for fiscal year 2025.
- Janux Therapeutics, Inc. showed a decrease of -87.8% in Cash and Equivalents compared to the prior fiscal year.
- Janux Therapeutics, Inc. reported Stockholders Equity of $956.82 million for fiscal year 2025.
- Janux Therapeutics, Inc. showed a decrease of -6.4% in Stockholders Equity compared to the prior fiscal year.
- Janux Therapeutics, Inc. reported R&D Expense of $125.90 million for fiscal year 2025.
- Janux Therapeutics, Inc. showed an increase of +84.1% in R&D Expense compared to the prior fiscal year.
- Janux Therapeutics, Inc. reported Operating Income of -$157.67 million for fiscal year 2025.
- Janux Therapeutics, Inc. showed a decrease of -59.5% in Operating Income compared to the prior fiscal year.
- Janux Therapeutics, Inc. reported Shares Outstanding of 60.38 million shares for fiscal year 2025.
- Janux Therapeutics, Inc. showed an increase of +2.2% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: